Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

University Children's Hospital Tuebingen

Overview

Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.

Study Type

OBSERVATIONAL

Conditions

Systemic Aspergillosis Systemic Candidiasis

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pediatric patients under the age of 18 years * Pediatric patients after HSCT treated with caspofungin * Pediatric patients after HSCT treated with liposomal amphotericin Exclusion Criteria: * Pediatric patients with uncontrolled hematological malignancies * Pediatric patients with IFI at start of HSCT

Locations (1)

University Children's Hospital

Tübingen, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.